JPRN-jRCT2080220688未知1 期
An open label, intra-patients dose ascending, repeated administration study of subcutaneous injection of MRA in patients with rheumatoid arthritis
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with RA diagnosed according to the revised 1987 ACR. CRP or ESR at screening is >1mg/dL or >30 mm/h, respectively.
- •Non responder or inadequate response patients who receive at least one DMARD or immunosuppressant.
排除标准
- •Patients who are treated with biologics and/or leflunomide within 6 weeks before treatment.
- •Patient's WBC, Neutrophil count and lymphocyte count are less than 3500, 1000 and 500/microL, respectively.
研究者
相似试验
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the CAN04 antibody, in patients with solid malignant tumors.EUCTR2017-001111-36-NLCantargia AB116
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the CAN04 antibody, in patients with solid malignant tumors.EUCTR2017-001111-36-DKCantargia196
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the CAN04 antibody, in patients with solid malignant tumors.EUCTR2017-001111-36-DECantargia AB196
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the CAN04 antibody, in patients with solid malignant tumors.EUCTR2017-001111-36-LVCantargia AB196
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the CAN04 antibody, in patients with solid malignant tumors.EUCTR2017-001111-36-ATCantargia AB116